COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
Read article
News
Featured news
COMPANY NEWS
COMPANY NEWS
2 min read
100+ Locations and Growing: A Milestone for FebriDx® Adoption
FebriDx® has surpassed 100 healthcare locations across 18 states in the United States
Read article
COMPANY NEWS
1 min read
Lumos Achieves 250 Patient Milestone in FebriDx® Paediatric Study
Lumos has achieved enrolment of 250 patients in its BARDA-funded FebriDx® paediatric clinical study, triggering a US$670,000 milestone payment...
Read articleAll news
COMPANY NEWS
1 min read
Proactive Interview with CFO Barrie Lambert
In this interview, Lumos’ CFO Barrie Lambert discusses Lumos’ upcoming paediatric study designed to expand FebriDx®...
Read article
COMPANY NEWS
1 min read
Lumos Diagnostics Signs Second ANZ Distribution Agreement for FebriDx®
Lumos Diagnostics has signed a new distribution agreement with Amtech, part of the YesGroup alliance
Read article
COMPANY NEWS
1 min read
Lumos FY25 Results Investor Briefing
During this briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell provide an overview of the FY25 results and a general business update.
Read article
COMPANY NEWS
1 min read
Lumos secures follow-on contract with Aptatek Biosciences for development of PKU in-home monitoring device
Lumos has secured a follow-on contract with Aptatek Biosciences to advance the PheCheck™ in-home monitoring device for phenylketonuria (PKU).
Read article
COMPANY NEWS
1 min read
Lumos and BARDA partner to undertake an additional clinical study to evaluate use of FebriDx®in U.S. CLIA-waived pediatric settings
Lumos Diagnostics has announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded US$6.2 million in non-dilutive funding to support a new U.S. paediatric study of our flagship FebriDx® test.
Read article
COMPANY NEWS
2 min read
Submission of CLIA Waiver Application for FebriDx®
Lumos Diagnostics has announced the completion of the clinical study and submission of its application to the U.S...
Read article
COMPANY NEWS
2 min read
Lumos Diagnostics Partners with PRO-spectus to Accelerate Market Access for FebriDx
Lumos Diagnostics has today announced that it has entered into a partnering agreement with US-based market access consultancy...
Read article
COMPANY NEWS
1 min read
Lumos Signs Binding Term Sheet for A$5.0 million Loan Facility
Lumos has announced a binding A$5.0 million secured loan facility with major shareholders, Tenmile and Ryder Capital.
Read article
COMPANY NEWS
2 min read
Lumos Diagnostics Signs Exclusive U.S. Distribution and Supply Agreement with PHASE Scientific for FebriDx®
Lumos has today announced a pivotal commercial development for its breakthrough diagnostic product, FebriDx®
Read article
COMPANY NEWS
1 min read
Video | Investor Briefing | PHASE Scientific Agreement
Lumos held an investor briefing outlining the transformational US$317 million distribution agreement with PHASE Scientific.
Read article
COMPANY NEWS
1 min read
Lumos Diagnostics Reaches 50% Recruitment Milestone in FebriDx CLIA Waiver Clinical Study
Lumos Diagnostics has announced that the Company has now successfully achieved 61 bacterial positive patients, representing 50% of the target of 120 bacterial positive patient results required for the study...
Read article
COMPANY NEWS
1 min read
Lumos Secures Sixth US Medicare Reimbursement for FebriDx®
Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), CGS Administrators...
Read article